Clinical Trials Directory

Trials / Sponsors / PharmaMar

PharmaMar

Industry · 48 registered clinical trials4 currently recruiting.

StatusTrialPhaseStarted
RecruitingStudy of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Par
Leiomyosarcoma
Phase 32023-09-21
RecruitingClinical Trial of PM54 in Advanced Solid Tumors Patients.
Advanced Solid Tumor
Phase 12023-04-28
TerminatedPlitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospita
COVID-19
Phase 22023-04-19
RecruitingPM534 Administered Intravenously to Patients With Advanced Solid Tumors
Patients With Advanced Solid Tumors
Phase 12022-12-23
Active Not RecruitingClinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotec
Relapsed Small Cell Lung Cancer
Phase 32022-07-22
CompletedExtension Study in a Cohort of Adult Patients With COVID-19 Infection
COVID-19 Infection
Phase 1 / Phase 22022-01-25
TerminatedTrial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
COVID-19 Infection
Phase 32021-06-04
UnknownClinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of
Advanced Solid Tumor, Hepatic Impairment
Phase 12021-03-09
CompletedStudy to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced So
Advanced Solid Tumor
Phase 12021-01-14
CompletedClinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Phase 12020-10-07
CompletedProof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
COVID-19
Phase 12020-05-12
CompletedClinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Phase 22018-01-16
RecruitingPM14 Administered Intravenously to Patients with Advanced Solid Tumors
Advanced Solid Tumor
Phase 12017-09-06
TerminatedTrial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients
Multiple Myeloma
Phase 22017-05-08
TerminatedA Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Lymphoma
Phase 22016-10-25
CompletedClinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Sm
Small-cell Lung Cancer
Phase 32016-08-30
CompletedPharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST)
Phase 1 / Phase 22016-05-06
CompletedClinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Advanced Solid Tumors
Phase 22015-08-25
CompletedEvaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid
Solid Tumors
Phase 22015-08-12
CompletedNon-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patie
Relapsed Ovarian Cancer
2015-07-28
CompletedClinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Ovarian Cancer
Phase 32015-05-01
CompletedMulticenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Sel
Solid Tumors
Phase 12014-12-12
CompletedStudy of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Advanced Solid Tumors
Phase 12014-07-30
CompletedStudy of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Mye
Multiple Myeloma
Phase 12014-06-01
CompletedA Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Contro
Non-Small Cell Lung Cancer (NSCLC)
Phase 22013-09-11
CompletedPhase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selec
Breast Cancer, Ovarian Cancer, Gynecological Cancer
Phase 12013-09-01
CompletedStudy of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (M
Metastatic Breast Cancer, Pancreatic Cancer, Metastatic Colorectal Cancer
Phase 12013-04-01
CompletedA Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Breast Cancer
Phase 22012-06-13
CompletedStudy of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
Major Advanced Solid Tumors Other Than Colorectal
Phase 12011-11-01
CompletedStudy Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unr
Endometrial Adenocarcinomas, Neuroendocrine Tumors, Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Phase 12011-05-25
CompletedClinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Acute Leukemia
Phase 12011-05-01
CompletedEscalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumor
Specific Advanced Solid Tumors
Phase 12011-05-01
CompletedStudy of PM060184 in Patients With Advanced Solid Tumors
Solid Tumors
Phase 12011-01-01
CompletedStudy in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide
Soft Tissue Sarcoma
2010-12-01
CompletedStudy of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of
Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall
Phase 22010-12-01
CompletedClinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Myelofibrosis
Phase 22010-07-01
CompletedAplidin - Dexamethasone in Relapsed/Refractory Myeloma
Relapsed/Refractory Multiple Myeloma
Phase 32010-06-01
TerminatedClinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Canc
Uterine Cervical Cancer, Endometrial Cancer
Phase 22009-08-01
CompletedPhase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients W
ADVANCED SOLID TUMORS
Phase 12009-03-01
CompletedTrial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Advanced Malignant Solid Tumors
Phase 12009-01-01
CompletedStudy of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Ly
Advanced Solid Tumors, Lymphomas
Phase 12008-12-01
TerminatedClinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory L
Relapsed/Refractory Leukemia
Phase 1 / Phase 22007-11-01
TerminatedA Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
Solid Tumors, Lymphoma
Phase 12006-05-01
TerminatedA Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
Solid Tumors
Phase 12005-08-01
TerminatedA Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
Prostate Cancer
Phase 22005-02-01
CompletedA Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Multiple Myeloma
Phase 22005-02-01
CompletedMulticenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
Leukemia, Lymphoma
Phase 22004-12-01
TerminatedEcteinascidin 743 in Treating Patients With Malignant Mesothelioma
Malignant Mesothelioma
Phase 22001-07-01